Key Features and Values
– High sensitivity assays provide accurate measurements leading to improved performance in clinical use
– Same sample type can be used across all assays to simplify inclusion into routine serology work-up and provide a cost effective solution
– Long shelf life cost-effective solution by reducing wastage due to expired kits
– Suitable for inclusion on automated plate systems simplifies scale-up of test volume
– Supported by a panel of assays for supporting early detection and differential diagnosis of diabetes type I and II
C-Peptide ELISA kit is a direct solid phase enzyme immunoassay for the quantitative determination of C-Peptide in human serum or plasma. C-Peptide ELISA kit is intended for laboratory use only.
C-Peptide is the abbreviation for connecting peptide, it is a 31-amminoacid peptide. C-Peptide of insulin is the C-terminal cleavage product produced during processing of the insulin prohormone to the mature insulin molecule. Proinsulin is cleaved when it is released from the pancreas into the blood – with one C-Peptide for each insulin molecule. C-Peptide is devoid of any biological activity but appears to be necessary to maintain the structural integrity of Insulin. In-vitro determination of Insulin and C-Peptide level help in the differential diagnosis of liver disease, acromegaly, Cushing sindrome, familial glucose intolerance, insulinimia, renal failure, ingestion of accidental oral hypoglicemic drugs or C-Peptide induced factitious hypoglicemia.
Newly diagnosed diabetes patient often get their C-Peptide levels measured, to find if they have type 1 or type 2 diabetes. The pancreas of patients with type 1 diabetes is unable to produce insulin and they will therefore usually have a decreased level of C-Peptide; while C-Peptide levels in type 2 patients is normal or higher than normal. Measuring C-Peptide in patients injecting insulin can help to determine how much of their own natural insulin these patients are still producing.
C-Peptide assays may be analytically more sensitive than insulin assays. Measurement of the C-Peptide may be useful in evaluating endogenous insulin secretion in a variety of clinical conditions. Insulin and C-Peptide are secreted into portal circulation in equimolar concentrations, fasting levels of C-Peptide are 5 – 10 fold higher than those of Insulin owing to the longer half-life of C-Peptide. The liver does not extract C-Peptide however; it is removed from the circulation by degradation in the kidneys with a fraction passing out unchanged in urine. Hence the urine C-Peptide levels correlate well with fasting C-Peptide levels in serum.